Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 16/20 | 0.52 |
| ▸ | WNT3A | P56704 | 1/20 | 0.47 |
| ▸ | PGK1 | P00558 | 1/20 | 0.46 |
| ▸ | CKS1B | P61024 | 2/20 | 0.46 |
| ▸ | SKP1 | P63208 | 2/20 | 0.46 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22579215 | 0.89 | CKS1B (0.50) | RETWNT3APGK1CKS1BSKP1 | |
| SCHEMBL22579238 | 0.87 | ABCB1 (0.51) | RET | |
| SCHEMBL22641741 | 0.87 | RET (0.56) | RETWNT3ACKS1BSKP1SKP2 | |
| SCHEMBL20128887 | 0.87 | GPR119 (0.52) | RETWNT3APGK1CKS1BSKP1 | |
| SCHEMBL20214374 | 0.87 | GPR119 (0.52) | RETWNT3APGK1CKS1BSKP1 | |
| SCHEMBL22579193 | 0.86 | RET (0.49) | RETWNT3APGK1 | |
| SCHEMBL22579192 | 0.81 | RET (0.46) | RETWNT3A | |
| SCHEMBL23640630 | 0.80 | CKS1B (0.47) | WNT3ACKS1BSKP1SKP2 | |
| SCHEMBL29943946 | 0.80 | CKS1B (0.47) | WNT3ACKS1BSKP1SKP2 | |
| SCHEMBL10317400 | 0.79 | SMN1; SMN2 (0.54) | RETWNT3APGK1CKS1BSKP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3736266-A1 | COMPOUND SIMULTANEOUSLY INHIBITING LSD1 AND HDAC TARGETS AND APPLICATION THEREOF | Peking University Shenzhen Graduate School (CN) | 2020-11-11 | — | — | EP | disclosed |
| US-20200331882-A1 | COMPOUND FOR SIMULTANEOUSLY INHIBITING LSD1 AND HDAC TARGETS AND APPLICATION THEREOF | PEKING UNIVERSITY SHENZHEN GRADUATE SCHOOL (CN) | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331882-A1 | COMPOUND FOR SIMULTANEOUSLY INHIBITING LSD1 AND HDAC TARGETS AND APPLICATION THEREOF | HDAC1, HDAC3, HDAC11 | RET 1970/4885WNT3A 1535/4885PGK1 1921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.